# NAD+ Research: Mechanism, Human Trials, IV Therapy, Safety | NAD+ > NAD+ research summarized: the redox and signaling mechanism, the human precursor trials, intravenous NAD+ as an unapproved compounded therapy, tolerability, and the open questions. Cited. The redox-and-signaling biochemistry, the controlled precursor trials, the weak IV-therapy evidence, and the tolerability record — each finding logged to the study that measured it. ## Start here NAD+ research splits into two halves. The *mechanism* half is mature and well agreed: we know what NAD+ does in the cell, which enzymes consume it, and why its levels fall with age. The *human-benefit* half is younger and thinner: precursors clearly raise blood NAD+, but whether that helps people live longer or healthier is not settled. This page walks both halves and flags where the evidence is strong and where it is genuinely uncertain, citing each claim. ## The Mechanism: Redox Carrier and Consumed Signaling Substrate NAD+ is the cell's central electron carrier. It cycles between oxidized NAD+ and reduced NADH to move electrons through glycolysis, the TCA cycle, and oxidative phosphorylation — the chemistry that produces ATP [9][10]. A foundational review frames NAD+ as a coenzyme present in all living cells that both carries electrons in redox reactions and serves as a cosubstrate for signaling enzymes, with cellular concentrations shifting during aging [8]. The signaling role is what makes NAD+ a depletable resource. Sirtuins (SIRT1-7), PARP1, and the ectoenzyme CD38 all *consume* NAD+ to function — sirtuins for deacylation, PARP1 for DNA repair, CD38 as an NAD glycohydrolase [5]. Because these enzymes compete for one pool, prolonged disequilibrium of NAD+ metabolism has been linked to metabolic disease, cancer, aging, and neurodegeneration in mechanistic reviews [10]. ## Why NAD+ Declines With Age Tissue NAD+ falls with age across yeast, worms, mice, and humans [5][7]. A principal driver is CD38: its activity rises with age and inflammation, and it is the main NAD+-consuming ectoenzyme behind the decline. In mice, deleting CD38 preserved NAD+ levels and SIRT3 activity and improved mitochondrial function with age [2]. This decline is the rationale for boosting NAD+ with precursors. NAD+ biosynthesis is also essential in specific tissues: photoreceptor-specific deletion of the NAD+ enzyme NAMPT caused retinal degeneration in mice that NMN could rescue, identifying NAD+ synthesis as essential for vision [11]. ## How NAD+ Is Delivered in the Literature Two delivery strategies dominate the research, and they are not equivalent. The well-supported route is oral *precursors* — NMN, NR, and nicotinamide capsules and powders — which carry the bulk of controlled human evidence and reliably raise blood NAD+ over days to weeks [3][4]. NAD+ therapy in this oral-precursor form is what most rigorous trials actually tested. The second route is direct NAD+ infusion or injection, marketed as IV NAD+ therapy. It is compounded, not FDA-approved, and supported by minimal controlled data. The two routes should never be conflated: a study of oral NR is not evidence for an IV NAD+ drip. ## Intravenous NAD+: An Unapproved Compounded Wellness Therapy NAD IV therapy delivers NAD+ directly into the bloodstream as a compounded wellness treatment. It is not FDA-approved, and the controlled evidence is the weakest in the field. A pharmacokinetic concern compounds the problem: infused NAD+ is rapidly cleared from plasma, with near-complete removal within roughly the first two hours of infusion, suggesting much of it is metabolized extracellularly rather than delivered intact to cells. There are also documented quality risks. A compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin contamination. Infusions run too quickly can cause chest tightness, nausea, flushing, and abdominal discomfort, which is why published reports describe slow multi-hour infusions. This site presents IV NAD+ as an unapproved compounded therapy with limited evidence and documented quality concerns — not as an approved treatment, and with no administration instructions. ## Tolerability and Reported Adverse Events Oral precursors have a reassuring controlled-trial record. NR at up to 1000 mg/day for 8 weeks showed no significant adverse-event difference from placebo and no flushing [4]. NMN at 300-900 mg/day for 60 days reported no safety issues at any dose [3], and NMN at 250 mg/day for 10 weeks was well tolerated [1]. NR has been tested for safety as high as 3000 mg/day in a Parkinson's disease trial. The NAD+ side effects that do appear cluster around the IV route and product quality: infusion symptoms when run too fast, and the endotoxin contamination behind the Class I recall of a compounded injectable. A theoretical oncology caution also exists — because NAD+ supports proliferating cells, its roles in cancer are dual and context-dependent, so caution is advised in cancer populations. --- A color-coded poster wall of the NAD+ record — the coenzyme, its oral precursors NMN and NR, and the thin IV-therapy evidence each set in its own block and cited to the study that measured it, with the precursor-not-NAD+ distinction kept exact; no clinic behind the wall and nothing here dosed, compounded, prescribed, or sold.